STOCK TITAN

Neuropace, Inc. - NPCE STOCK NEWS

Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.

NeuroPace, Inc. is a leading commercial-stage medical device company based in Silicon Valley, focused on transforming the lives of individuals suffering from epilepsy. Founded with the mission to design, develop, manufacture, and market implantable devices for neurological disorders, NeuroPace has made significant strides in the field of responsive neurostimulation.

At the core of NeuroPace's innovation is the RNS® System. This award-winning technology, akin to a pacemaker for the heart, is the world's first and only medical device capable of monitoring and responding to brain activity in real-time. The RNS® System is specifically designed to treat epilepsy, a neurological disorder that affects approximately 1% of the global population, by reducing or eliminating debilitating seizures. The system is primarily used in hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).

Beyond epilepsy, the promise of responsive neurostimulation extends to several other disabling medical conditions, potentially improving the quality of life for millions worldwide. NeuroPace is recognized for its patient-centric approach and continuous advancements in the field of neurological treatments.

Recent achievements include the RNS® System being featured in over 50 scientific presentations and posters, underscoring its impact and the ongoing research dedicated to improving its efficacy. The company also maintains significant partnerships and collaborations to further its mission and ensure the RNS® System remains at the forefront of medical innovation.

Financially, NeuroPace derives nearly all its revenue from the sales of the RNS® System, highlighting the product's centrality to the company’s business model. With a strong focus on patient outcomes and continuous technological advancement, NeuroPace is well-positioned to lead in the field of neurological disorder treatments.

Rhea-AI Summary
NeuroPace, a medical device company specializing in epilepsy treatment, will release its first-quarter 2024 financial results on May 8, 2024. The management will host a conference call for investors to discuss the results. Interested parties can access the live webcast or participate via telephone. The webcast will be archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
conferences earnings
-
Rhea-AI Summary
NeuroPace, Inc. (NPCE) to present at the Needham 23rd Annual Healthcare Conference. CEO Joel Becker to provide a corporate presentation on April 8. The company focuses on epilepsy treatment and will engage in investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
conferences
-
Rhea-AI Summary
NeuroPace, Inc. (NPCE) reported a 41% increase in revenue to $18.0 million in Q4 2023 compared to Q4 2022, a 44% increase to $65.4 million in 2023 over 2022. The company provided a revenue guidance of $73-$77 million for 2024. Initiatives like Project CARE and the NAUTILUS study show strategic growth plans. Gross margin increased to 75.2% in Q4 2023. Operating expenses were effectively managed, resulting in a reduced cash burn of $3.4 million in Q4 2023. Full-year 2023 revenue grew 44% to $65.4 million, with a focus on RNS System sales and DIXI Medical products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
Rhea-AI Summary
NeuroPace, Inc. (NPCE) to Report Q4 and Full Year 2023 Financial Results on March 5, 2024. The company will host a conference call for investors to discuss the results. Webcast and call details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
conferences earnings
-
Rhea-AI Summary
NeuroPace, Inc. (NPCE) expects Q4 2023 revenue between $17.5-18.0 million, with full-year 2023 revenue between $64.9-65.4 million. The company also announced a cash balance of $66.5 million and completed milestones in patient implant, data collaboration, and a pilot program. The NAUTILUS trial for epilepsy treatment is progressing ahead of schedule. The company's CEO expressed satisfaction with 2023 accomplishments and optimism for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.89%
Tags
none
-
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) completes patient enrollment goal in its NAUTILUS pivotal study for the treatment of idiopathic generalized epilepsy (IGE) more than one quarter ahead of schedule. The RNS System could secure the first device-based indication for generalized epilepsy, addressing the treatment gap for the 1.2 million drug refractory epilepsy patients in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
none
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
conferences
-
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) announced a strategic collaboration with a clinical-stage biotechnology company to leverage RNS System’s unique biomarker monitoring and data analysis capabilities. The collaboration involves tracking responses of implanted RNS System patients enrolled in the biotechnology company’s clinical trial. NeuroPace will receive up to $3.7 million over two years for providing non-exclusive access to its proprietary biomarker monitoring and data analysis capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
-
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) will have a substantial presence at the 77th American Epilepsy Society Annual Meeting, featuring over 50 scientific presentations and posters regarding the RNS System, a therapy option for drug resistant epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
Rhea-AI Summary
NeuroPace, Inc. (NPCE) to present at Piper Sandler 35th Annual Healthcare Conference, with CEO Joel Becker providing a corporate presentation on November 28 at 2:30pm ET. The company will also participate in one-on-one meetings with investors during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences

FAQ

What is the current stock price of Neuropace (NPCE)?

The current stock price of Neuropace (NPCE) is $6.335 as of November 4, 2024.

What is the market cap of Neuropace (NPCE)?

The market cap of Neuropace (NPCE) is approximately 182.8M.

What is NeuroPace, Inc. known for?

NeuroPace is known for its innovative RNS® System, the first and only medical device that monitors and responds to brain activity to treat epilepsy.

What medical condition does the RNS® System primarily target?

The RNS® System primarily targets epilepsy, helping to reduce or eliminate debilitating seizures.

Where is NeuroPace, Inc. based?

NeuroPace, Inc. is based in Silicon Valley.

How does the RNS® System work?

Similar to a pacemaker for the heart, the RNS® System monitors brain activity in real-time and responds with electrical stimulation to prevent seizures.

Who are the primary customers for the RNS® System?

The primary customers are hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).

What recent achievements has NeuroPace made?

The RNS® System has been featured in over 50 scientific presentations and posters, showcasing its impact and ongoing research.

How does NeuroPace generate revenue?

NeuroPace generates revenue predominantly through the sales of the RNS® System.

Can the RNS® System treat conditions other than epilepsy?

Yes, responsive neurostimulation holds the promise of treating several other disabling medical disorders.

What makes the RNS® System unique?

The RNS® System is the world’s first and only device that can monitor and respond to brain activity in real-time to treat neurological disorders.

Who can be contacted for investor-related inquiries at NeuroPace?

Jeremy Feffer, Managing Director at LifeSci Advisors, can be contacted for investor-related inquiries.

Neuropace, Inc.

Nasdaq:NPCE

NPCE Rankings

NPCE Stock Data

182.77M
29.20M
4.19%
83.53%
1.74%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MOUNTAIN VIEW